• Chengdai Yuan, Wei Luo, Xiaocao Ren, Maxiao Ya, Wenlong Yan, and Quanbin Hui.
• Department of Pharmacy, Baoji Traditional Chinese Medicine Hospital, Baoji, Shanxi.
• Medicine (Baltimore). 2021 Apr 23; 100 (16): e25437e25437.

BackgroundAtrial fibrillation (AF) is the most common clinical arrhythmia and a major cause of morbidity and mortality in clinical practice. This study aims to determine the ranolazine for prevention and treatment of atrial fibrillation.MethodThis study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analysis for Protocols. Chinese electronic Database (CBM, Wanfang, and CNKI) and international electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) will be searched for all relevant published articles. We will apply no language or the year of publication restrictions. Study selection, data collection, and assessment of study bias will be conducted independently by a pair of independent reviewers. The Cochrane risk of bias (ROB) tool will be used for the risk of bias assessment. The quality of evidence will be evaluated by Grading of Recommendations Assessment Development and Evaluation (GRADE) system. The statistical analysis of this meta-analysis will be calculated by Review manager version 5.3.ResultsThe results of this study will be published in a peer-reviewed journal.ConclusionThis review will evaluate the value of ranolazine interventions for patients with AF, and provide meaningful conclusions or high-level evidence for clinical practice and further research.Trial RegistrationThis study protocol was registered in open Science framework (OSF), (Registration DOI: 10.17605/OSF.IO/T6W9Q).Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

34 keywords...

hide…